Patients with hematological malignancies are at an increased risk of SARS-CoV-2 disease (COVID-19) and adverse outcome. However, a low mortality rate has been reported in patients with chronic myeloid leukemia (CML). Preclinical evidence suggests that tyrosine kinase inhibitors (TKIs) may have a protective role against severe COVID-19.
|Titolo:||The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population|
BONIFACIO, Massimiliano (Corresponding)
|Data di pubblicazione:||2021|
|Appare nelle tipologie:||01.01 Articolo in Rivista|